On February 21, 2019, Sandoz Inc. (“Sandoz”) filed suit against Amgen Inc. and Amgen Manufacturing Limited (collectively “Amgen”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
pegfilgrastim
-
-
RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Amgen initiated suit against Apotex in the Middle District of Florida, alleging infringement of U.S. Patent No....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, the U.S. FDA announced approval of Mylan’s Fulphila biosimilar to Neulasta® (pegfilgrastim). Neulasta® was...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, on April 18, 2018, Judge Stark in the District of Delaware entered the Final Judgment and Order dismissing the patent...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Biologic drugs are large molecules, such as therapeutic proteins, DNA vaccines, monoclonal antibodies, and fusion proteins, that are...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sandoz announced that its biosimilar application for Neulasta® (pegfilgrastim) has been accepted for regulatory review by the European...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Biologic drugs are quickly reshaping the pharmaceutical landscape as they dominate the drug market in annual sales revenue. Abbvie’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction and Background The Apotex filgrastim/pegfilgrastim biosimilar litigation was the first biosimilar litigation where the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]